BioSpace News Archive

Generation Bio Co. is an innovative genetic medicines company creating a new class of non-viral gene therapy.

BioCardia®, Inc. reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that management will present at the following upcoming virtual investor conferences: Event: Stifel 2020 Virtual Healthcare Conference Date: Tuesday, November 17, 2020 Presentation Ti

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference

- Patented methods form the foundation of clinical-stage allogeneic CAR T-cell therapies - Other applications include allogeneic stem cell-derived therapies and therapeutic gene editing for the treatment of genetic diseases - Additional patents pending in the U.S. and other countries

- Multi-dosing portion of Fusion’s Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation radiopharmaceuticals

Transformative long-term weight loss results show 95% of total body weight loss achieved during Elipse Balloon treatment was maintained at 1-year Sequential balloon treatment achieves weight loss at 1-year that approximates bariatric surgery

TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response QIAGEN Secures Option to License Discoveries from TScan’s TCR/Target ID Platform for Use in Potential Diagnostics for COVID-19

Program to Support Weekly Testing of Up to 9,000 Faculty and Staff at Peak Operations, Equates to Use of Approximately 1,800 Tests per Week; Applied DNA Receives Initial Stocking Order Under Master Services Agreement

Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference